As engine maker Cummins prepares to report fourth-quarter results, investors are watching for signs of resilience in the face of slowing demand and shifting industry dynamics.
StepStone Group is set to report its fourth-quarter earnings after the market closes on Thursday. Analysts project robust revenue growth, but the firm faces a challenging macro backdrop and recent stock underperformance.
Carrier Global (NYSE: CARR) is scheduled to release its fourth-quarter earnings before market open on Thursday, with analysts anticipating a modest revenue decline but watching for signs of operational strength in a buoyant sector.
Alternative investment giant Ares Management (ARES) is scheduled to release its fourth-quarter financial results before Thursday's market open, with analysts anticipating strong year-over-year revenue growth despite recent sector headwinds.
Infrastructure specialist Construction Partners (NASDAQ: ROAD) is poised to release its fourth-quarter results Thursday morning. With mixed performance last quarter and shifting analyst expectations, here’s a breakdown of what investors should watch.
AGCO is set to report its fourth-quarter earnings before the bell on Thursday, with analysts forecasting a year-over-year revenue decline. Investors will be watching closely for signs of resilience in the agricultural equipment sector.
As Haemonetics prepares to report its fiscal fourth-quarter results, investors are watching for signs of stabilization after a period of declining revenues and a significant stock price drop. The report will shed light on the company's performance amid a mixed landscape for medical equipment peers.
The iconic fashion house Ralph Lauren (NYSE:RL) is scheduled to release its fourth-quarter financial results before Thursday's market open. Analysts project a slowdown in revenue growth compared to last year's strong performance, setting the stage for a closely watched report.
As QuinStreet prepares to report its fiscal fourth-quarter results, investors are watching for signs of stability after a period of significant stock price pressure. Analysts anticipate a year-over-year revenue dip, setting the stage for a critical update on the company's trajectory.
All eyes are on Ladder Capital (LADR) as it prepares to release its quarterly results amid a challenging commercial real estate landscape and a track record of recent misses.
Former Brevard County elementary school principal Elizabeth Hill-Brodigan received probation after pleading no contest to charges related to a massive underage drinking party at her home, a case that has sparked debate over accountability for educators.
Minnesota's top corrections official voices frustration over vague federal plans to scale back a controversial immigration operation, citing eroded trust and demanding transparency in the investigation of two agent-involved shootings.
After years of declining share prices, Pfizer is banking on a pipeline packed with over 20 pivotal Phase 3 trial launches this year to reignite growth and investor confidence.
Amid a sharp sell-off in growth-oriented sectors, risk-averse capital flowed into stable, income-generating giants on Tuesday, highlighting a broader market rotation.
Netflix's proposed acquisition of Warner Bros. Discovery, valued at $82.7 billion, is undergoing intense antitrust scrutiny. U.S. regulators and lawmakers are examining the deal's potential impact on streaming competition, content diversity, and the future of live sports broadcasting, including the Olympics.
Federal immigration authorities have arrested a New Orleans police recruit just one week before his academy graduation, alleging the department issued him a firearm while he was under an active deportation order. The NOPD disputes the characterization, stating it followed standard verification procedures.
TransMedics Group, Inc. (TMDX), a pioneer in portable organ perfusion technology, is drawing significant investor interest. With its shift to a recurring revenue model and FDA approvals expanding its market, the company presents a compelling growth story in the medtech sector, despite a premium valuation.
As Teva Pharmaceutical shifts focus from its legacy generics business to a promising innovative pipeline, its experimental drug Duvakitug emerges as a potential valuation catalyst. We examine the bull case, the competitive landscape, and what it means for investors.
Penumbra, Inc. (NYSE: PEN), a dominant force in thrombectomy devices, has seen its stock retreat amid a broad market shift away from healthcare. With fundamentals intact and a debt-free balance sheet, analysts see the dip as a buying opportunity ahead of key catalysts.
The Clorox Company reported fiscal second-quarter results largely in line with internal forecasts, citing a challenging macro environment and temporary disruptions from its ongoing ERP system implementation. Management highlighted sequential improvement through the quarter and outlined a path to margin recovery and growth driven by innovation in the latter half of the fiscal year.
